68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Christian SchmidkonzMichael CordesDaniela SchmidtTobias BäuerleTheresa Ida GoetzMichael BeckOlaf PranteAlexander CavallaroMichael UderBernd WullichPeter GoebellTorsten KuwertPhilipp Ritt

Published in: European journal of nuclear medicine and molecular imaging (2018)

68Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. Especially, TL-PSMA demonstrated higher agreement rates with biochemical response compared to SUVmax. Larger, ideally prospective trials are needed to help to reveal the full potential of metabolic parameters derived from PET imaging with 68Ga-PSMA-11.

Keyphrases

pet ct
pet imaging
prostate cancer
positron emission tomography
radical prostatectomy
genome wide
computed tomography
risk assessment
single cell
dna methylation
risk factors
high resolution
solid phase extraction